Document is current
Any future updates will be listed below
-
Authors
Szijj, Peter A. https://orcid.org/0000-0002-2944-2676
Gray, Melissa A.
Ribi, Mikaela K. https://orcid.org/0000-0001-6816-8326
Bahou, Calise
Nogueira, João C. F. https://orcid.org/0000-0002-5992-5900
Bertozzi, Carolyn R. https://orcid.org/0000-0003-4482-2754
Chudasama, Vijay https://orcid.org/0000-0002-8876-3285
-
Funding
Funding for this research was provided by:
Wellcome Trust (175282, 214941/Z/18/Z)
Foundation for the National Institutes of Health (NIH R01 CA227942)
Foundation for the National Institutes of Health (NIH R01 CA227942)
Foundation for the National Institutes of Health (NIH R01 CA227942)
Leverhulme Trust (RPG-2020-010)
EC | Horizon 2020 Framework Programme (675007)
- License Information
-
More Information
Article History
Received: 11 October 2022
Accepted: 21 June 2023
First Online: 24 July 2023
Competing interests
: M.A.G. and C.R.B. are inventors of a patent filed by Stanford University (international publication no. WO2018006034A1) titled ‘Conjugates for targeted cell-surface editing’ published on 4 January 2018 and licensed by Palleon Pharmaceuticals on 27 June 2017. C.R.B. is a cofounder and Scientific Advisory Board member of Palleon Pharmaceuticals, Enable Bioscience, Redwood Biosciences (a subsidiary of Catalent), InterVenn Biosciences, Lycia Therapeutics, Grace Science LLC and OliLux Biosciences. V.C. is a director of the spin-out ThioLogics and is an inventor of the patent filed by UCL Business PLC (European patent EP-2464654-B1) titled ‘Thiol protecting group’ published on 8 October 2014, and other patents derived thereof, as well as directly related patents in other jurisdictions that fall within the patent family. The remaining authors declare no competing interests.
